Depression in the Elderly and Cerebral Amyloid Plaques: Characterization by [18F] AV-45 Affective… (NCT01962753) | Clinical Trial Compass
CompletedNot Applicable
Depression in the Elderly and Cerebral Amyloid Plaques: Characterization by [18F] AV-45 Affectives Symptoms and Amyloïd Plaques (ASAP)
France92 participantsStarted 2012-05-10
Plain-language summary
The primary objective of the study is to compare the brain amyloid load in fully, partially and non remitting depressed elderly patients at 8 weeks of antidepressant therapy, by using PET with \[F18\]AV45.
Who can participate
Age range
55 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Exclusion criteria
. Metallic foreign body eye.
. Any implanted electronic medical irremovably (pacemaker, neurostimulator, cochlear implants ...)
. Metal heart valve,
. Vascular clips formerly located on cranial aneurysm.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study looked at amyloid plaques in the brains of elderly people with major depression using a PET scan tracer called [18F] AV-45 — does my situation suggest I should be evaluated for amyloid buildup, and would that kind of imaging be relevant to my care?
2Since this trial is completed and was measuring something called SUVr — a way of quantifying amyloid deposits in the brain — has the research found any meaningful link between depression in older adults and Alzheimer's-related changes that might affect how my depression should be treated?
3This study focused specifically on elderly patients with major depression, which sounds like it could relate to my diagnosis — can you help me understand whether the findings from this research change how you think about evaluating or managing depression in someone my age?
4Because this was not a treatment trial but rather a characterization study, it wasn't testing a new therapy — so is there a next step, like a treatment trial or imaging assessment, that you'd recommend I consider based on what studies like this have found?
5Given that this research explored a possible connection between depression and brain amyloid plaques, should I be thinking about cognitive monitoring as part of my overall care plan, and is that something worth discussing with a specialist?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.